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Introduction/Background
● Increasing rates of diabetes around the 
world
● Existing studies show the negative effect 
of diabetes on healthy eyes1,2
● Research that has shown that diabetic 
donor grafts perform the same as non-
diabetic donors3, but what about diabetic 
recipients?
Who is this study important to?
Research Question and Hypothesis
● Research Question: How does 
recipient diabetes status impact 
the rate of total immune graft 
rejection? 
● Research Hypothesis: diabetic 
patients will have a higher risk of 








Risk Factor Odds Ratio p-value 95% Confidence Interval
Diabetes 2.28 0.047 (1.01, 5.14)
HSV/VZV 7.61 0.005 (1.83, 31.54)
Reduced rejection-free mean survival time (years)
Patients with Diabetes 6.9
Patients without Diabetes 8.9
Conclusions
● Diabetic patients have a higher risk 









○ Severity of diabetes/pre-transplant 
treatment adherence 
○ Post-transplant diabetes treatment 
options 
● Implementation: more aggressive 
post-transplant steroid regimen 
management
○ Another potential study: what is the 
ideal regimen?
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